Veracyte (VCYT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Veracyte Revenue Highlights

Latest Revenue (Y)

$361.05M

Latest Revenue (Q)

$115.86M

Main Segment (Y)

Testing

Main Geography (Y)

UNITED STATES

Veracyte Revenue by Period

Veracyte Revenue by Year

Date	Revenue	Change
2023-12-31	$361.05M	21.76%
2022-12-31	$296.54M	35.09%
2021-12-31	$219.51M	86.85%
2020-12-31	$117.48M	-2.40%
2019-12-31	$120.37M	30.82%
2018-12-31	$92.01M	27.87%
2017-12-31	$71.95M	10.55%
2016-12-31	$65.08M	31.48%
2015-12-31	$49.50M	29.62%
2014-12-31	$38.19M	74.51%
2013-12-31	$21.88M	88.20%
2012-12-31	$11.63M	339.62%
2011-12-31	$2.65M	-

Veracyte generated $361.05M in revenue during NA 2023, up 21.76% compared to the previous quarter, and up 392.41% compared to the same period a year ago.

Veracyte Revenue by Quarter

Date	Revenue	Change
2024-09-30	$115.86M	1.25%
2024-06-30	$114.43M	18.16%
2024-03-31	$96.84M	-1.38%
2023-12-31	$98.20M	8.98%
2023-09-30	$90.11M	-0.24%
2023-06-30	$90.32M	9.58%
2023-03-31	$82.42M	2.65%
2022-12-31	$80.30M	6.22%
2022-09-30	$75.59M	3.74%
2022-06-30	$72.86M	7.50%
2022-03-31	$67.78M	0.66%
2021-12-31	$67.34M	11.54%
2021-09-30	$60.37M	9.55%
2021-06-30	$55.10M	50.14%
2021-03-31	$36.70M	6.27%
2020-12-31	$34.54M	10.97%
2020-09-30	$31.12M	50.31%
2020-06-30	$20.70M	-33.47%
2020-03-31	$31.12M	4.68%
2019-12-31	$29.73M	-4.01%
2019-09-30	$30.97M	2.78%
2019-06-30	$30.14M	2.06%
2019-03-31	$29.53M	14.68%
2018-12-31	$25.75M	9.73%
2018-09-30	$23.47M	3.14%
2018-06-30	$22.75M	13.52%
2018-03-31	$20.04M	2.27%
2017-12-31	$19.60M	11.86%
2017-09-30	$17.52M	-4.82%
2017-06-30	$18.41M	12.01%
2017-03-31	$16.43M	-10.00%
2016-12-31	$18.26M	-1.86%
2016-09-30	$18.60M	26.77%
2016-06-30	$14.68M	8.30%
2016-03-31	$13.55M	9.85%
2015-09-30	$12.34M	3.59%
2015-06-30	$11.91M	6.15%
2015-03-31	$11.22M	-8.04%
2014-12-31	$12.20M	24.00%
2014-09-30	$9.84M	13.38%
2014-06-30	$8.68M	16.06%
2014-03-31	$7.48M	9.33%
2013-12-31	$6.84M	22.24%
2013-09-30	$5.59M	10.38%
2013-06-30	$5.07M	15.60%
2013-03-31	$4.38M	-1.64%
2012-12-31	$4.46M	38.24%
2012-09-30	$3.22M	-

Veracyte generated $115.86M in revenue during Q2 2024, up 1.25% compared to the previous quarter, and up 128.27% compared to the same period a year ago.

Veracyte Revenue Breakdown

Veracyte Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Testing	$418.96M	$250.54M	$58.86M	$101.97M	$107.36M
Biopharmaceutical And Other	$13.15M	$33.36M	$19.87M	-	-
Product	$13.65M	$12.63M	$9.85M	$923.00K	-
Collaboration	-	-	-	-	$4.00M
Biopharmaceutical	-	-	-	$5.67M	$8.09M
Service	-	-	-	-	$250.00K
Fulfillment of Obligations	-	-	-	-	$4.00M
Provision of Data	-	-	-	-	$7.00M

Veracyte's latest annual revenue breakdown by segment (product or service), as of Dec 24: Testing (93.99%), Product (3.06%), and Biopharmaceutical And Other (2.95%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Sep 19	Jun 19
Testing	$219.12M	$109.54M	$90.30M	$326.54M	$81.75M	$72.40M	$70.27M	$64.58M	$59.72M	$16.37M	$16.07M	$31.50M	$26.99M	-	-	-	-	-	-	-
Biopharmaceutical And Other	$7.01M	$3.14M	$3.00M	$18.92M	$4.56M	$6.13M	$6.80M	$7.70M	$10.04M	$8.82M	$11.16M	$6.51M	-	-	-	-	-	-	-	-
Product	$6.92M	$3.19M	$3.54M	$15.59M	$4.01M	$3.89M	$3.23M	$3.31M	$3.11M	$2.98M	$2.96M	$2.69M	$3.06M	$2.70M	$2.03M	$1.71M	$3.41M	$90.00K	$90.00K	-
Biopharmaceutical	-	-	-	-	-	-	-	-	-	-	-	-	$1.62M	$566.00K	$343.00K	$824.00K	$3.78M	$722.00K	-	-
Collaborative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Service	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$250.00K	$250.00K
Provision of Data	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.20M
Provision of Data and Fulfillment of Milestones	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$3.20M

Veracyte's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Testing (94.02%), Biopharmaceutical And Other (3.01%), and Product (2.97%).

Veracyte Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20
Non-US	$22.23M	$33.61M	$18.53M	$7.87M
UNITED STATES	$423.54M	$262.92M	$200.98M	$109.61M

Veracyte's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (95.01%), and Non-US (4.99%).

Quarterly Revenue by Country

Country	Dec 24	Dec 23
UNITED STATES	$423.54M	$334.52M
Non-US	$22.23M	$26.53M

Veracyte's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (95.01%), and Non-US (4.99%).

Veracyte Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
VCYT	Veracyte	$361.05M	$115.86M
RYTM	Rhythm Pharmaceuticals	$130.13M	$29.08M
ANAB	AnaptysBio	$91.28M	$30.02M
ENTA	Enanta Pharmaceuticals	$67.64M	$16.96M
KURA	Kura Oncology	$53.88M	-
MRUS	Merus	$36.13M	$11.77M
MGTX	MeiraGTx	$33.28M	$10.91M
QURE	uniQure	$27.12M	$2.29M
SNDX	Syndax Pharmaceuticals	$23.68M	$12.50M
CYTK	Cytokinetics	$18.47M	$463.00K
IDYA	IDEAYA Biosciences	$7.00M	-
KROS	Keros Therapeutics	$3.55M	$37.00K
CRNX	Crinetics Pharmaceuticals	$1.04M	-
GPCR	Structure Therapeutics	-	-
SLDB	Solid Biosciences	-	-
PTGX	Protagonist Therapeutics	-	$4.67M
VTYX	Ventyx Biosciences	-	-
RCKT	Rocket Pharmaceuticals	-	-
VRDN	Viridian Therapeutics	-	$86.00K
REPL	Replimune Group	-	-

VCYT Revenue FAQ

What is Veracyte’s yearly revenue?

Veracyte's yearly revenue for 2023 was $361.05M, representing an increase of 21.76% compared to 2022. The company's yearly revenue for 2022 was $296.54M, representing an increase of 35.09% compared to 2021. VCYT's yearly revenue for 2021 was $219.51M, representing an increase of 86.85% compared to 2020.

What is Veracyte’s quarterly revenue?

Veracyte's quarterly revenue for Q2 2024 was $115.86M, a 1.25% increase from the previous quarter (Q1 2024), and a 28.58% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $114.43M, a 18.16% increase from the previous quarter (Q4 2023), and a 26.69% increase year-over-year (Q1 2023). VCYT's quarterly revenue for Q4 2023 was $96.84M, a -1.38% decrease from the previous quarter (Q3 2023), and a 17.50% increase year-over-year (Q4 2022).

What is Veracyte’s revenue growth rate?

Veracyte's revenue growth rate for the last 3 years (2021-2023) was 64.48%, and for the last 5 years (2019-2023) was 199.96%.

What are Veracyte’s revenue streams?

Veracyte's revenue streams in c 24 are Testing, Biopharmaceutical And Other, and Product. Testing generated $418.96M in revenue, accounting 93.99% of the company's total revenue, up 67.22% year-over-year. Biopharmaceutical And Other generated $13.15M in revenue, accounting 2.95% of the company's total revenue, down -60.57% year-over-year. Product generated $13.65M in revenue, accounting 3.06% of the company's total revenue, up 8.06% year-over-year.

What is Veracyte’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Veracyte was Testing. This segment made a revenue of $418.96M, representing 93.99% of the company's total revenue.